CTOs on the Move

LamdaGen Corp

www.lamdagen.com

 
LamdaGen Corp is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.lamdagen.com
  • 455 Adams Dr Ste 1155
    Menlo Park, CA USA 94025
  • Phone: 650.571.5816

Executives

Name Title Contact Details

Similar Companies

Hohenstein Institute America

Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gemin

Gemin

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Hyperion Biotechnology Inc

Hyperion Biotechnology Inc is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.